Searching for smart, safe news you can TRUST?

Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Searching for smart, safe news you can TRUST?

Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: George Frey/AFP via Getty Images

The Lancet medical journal retracted a study on Thursday that found that coronavirus patients who took hydroxychloroquine had a higher mortality rate and increased heart problem than those who did nothing, stating that the authors were "unable to complete an independent audit of the data underpinning their analysis."

Why it matters: The results of the study, which claimed to have analyzed data from nearly 96,000 patients on six continents, led several governments to ban the use of the anti-malarial drug for coronavirus patients due to safety concerns.

  • The World Health Organization also temporarily suspended its tests of hydroxychloroquine due to The Lancet study, before resuming them on Wednesday.

The big picture: An investigation by The Guardian found that employees at Surgisphere, the company that The Lancet relied on for its data, had little to no data science or scientific background.

  • “Surgisphere came out of nowhere to conduct perhaps the most influential global study in this pandemic in the matter of a few weeks," one doctor who publishes the results of hydroxychloroquine studies online told The Guardian.
  • It's unclear how Surgisphere was able to get data-sharing agreements with over 600 hospitals worldwide, and many in the scientific community had raised concerns about the reliability of its data.

What they're saying:

Today, three of the authors of the paper, "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis", have retracted their study. They were unable to complete an independent audit of the data underpinning their analysis. As a result, they have concluded that they "can no longer vouch for the veracity of the primary data sources." The Lancet takes issues of scientific integrity extremely seriously, and there are many outstanding questions about Surgisphere and the data that were allegedly included in this study.
— The Lancet

Zoom in: President Trump has frequently touted the use of hydroxychloroquine for COVID-19, turning the debate over the anti-malarial drug into a politically charged issue in the U.S.

  • Hydroxychloroquine prescriptions rose dramatically in March after the drug was brought into the political spotlight by Trump, with hydroxychloroquine and chloroquine fills increasing from 2019 levels by 1,977% between March 15–21.
  • Trump himself took the drug last month after two West Wing staffers tested positive for the virus.

Worth noting: Despite The Lancet's retraction, data from a randomized, placebo-controlled clinical trial published in the New England Journal of Medicine this week found that hydroxychloroquine did not prevent people from getting COVID-19 if they were exposed to the virus. The FDA has also issued a warning that the drug should only be taken in hospitals because of the risk of heart complications.

Go deeper

Updated 5 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Eniola Odetunde/Axios

  1. Vaccines: Key information about the effective COVID-19 vaccines — Oxford University's 90%-effective vaccine.
  2. Health: U.S. coronavirus hospitalizations keep breaking recordsWhy we're numb to 250,000 coronavirus deaths — Americans line up for testing ahead of Thanksgiving.
  3. Travel: Air travel's COVID-created future — Over 1 million U.S. travelers flew on Friday, despite calls to avoid holiday travel.
  4. World: England to impose stricter regional systemU.S. coronavirus hotspots far outpacing Europe's — Portugal to ban domestic travel for national holidays.
  5. Economy: The biggest pandemic labor market drags.
  6. Sports: Coronavirus precautions leave college basketball schedule in flux.

Michigan board certifies Biden's win

Poll workers count absentee ballots in Detroit, Michigan on Nov. 4. Photo: Salwan Georges/The Washington Post via Getty Images

The Michigan Board of State Canvassers certified the state's election results on Monday, making President-elect Joe Biden's win there official and granting him the state's 16 electoral votes.

Why it matters: Republican Party leaders had unsuccessfully appealed to delay the official certification, amid the Trump campaign's failed legal challenges in key swing states.

Biden to nominate Janet Yellen as Treasury secretary

Photo: Photo by Alex Wong/Getty Images

President-elect Joe Biden is preparing to nominate former Fed Chair Janet Yellen as his Treasury Secretary, four people familiar with the matter tell Axios.

Why it matters: Yellen, 74, will bring instant economic celebrity to Biden’s team and, if confirmed, she will not only be the first female Treasury Secretary but also the first person to have held all three economic power positions in the federal government: the chair of Council of Economic Advisers, the chair of Federal Reserve and the Treasury Secretary.